Stocks and Investing
Stocks and Investing
Tue, September 17, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
David Lebowitz Maintained (ASND) at Strong Buy with Increased Target to $207 on, Sep 17th, 2024
David Lebowitz of Citigroup, Maintained "Ascendis Pharma A/S" (ASND) at Strong Buy with Increased Target from $178 to $207 on, Sep 17th, 2024.
David has made no other calls on ASND in the last 4 months.
There are 6 other peers that have a rating on ASND. Out of the 6 peers that are also analyzing ASND, 0 agree with David's Rating of Hold.
These are the ratings of the 6 analyists that currently disagree with David
- Li Watsek of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $170 on, Monday, September 16th, 2024
- Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $175 on, Wednesday, September 4th, 2024
- Yaron Werber of "TD Cowen" Maintained at Strong Buy with Decreased Target to $157 on, Wednesday, September 4th, 2024
- Jessica Fye of "JP Morgan" Maintained at Buy with Decreased Target to $165 on, Wednesday, September 4th, 2024
- Kelly Shi of "Jefferies" Maintained at Strong Buy with Increased Target to $196 on, Tuesday, August 13th, 2024
- Alex Thompson of "Stifel" Initiated at Strong Buy and Held Target at $200 on, Friday, May 31st, 2024
Contributing Sources